By comparing mirror-image versions of cyclic peptides, researchers proved for the first time that the intestine uses active carrier proteins to transport peptides, not just passive diffusion — a finding that could transform oral peptide drug design.
First evidence of carrier-mediated peptide transportMirror-image peptides with identical physical properties showed different absorption across intestinal cells, proving that biological transport machinery — not just passive seeping — moves peptides across the gut wall
What the researchers found
The researchers tested enantiomeric pairs of five cyclic hexapeptides (three polar, two lipophilic) using two permeability assays. In the PAMPA assay (which measures only passive diffusion through an artificial membrane), all enantiomeric pairs showed identical permeability, as expected for mirror-image molecules with the same physical properties.
However, in the Caco-2 cell model (which contains biological transport machinery), the polar enantiomeric peptides showed significantly different permeability in both apical-to-basolateral and basolateral-to-apical directions. One lipophilic pair also showed differences, while the second lipophilic pair showed equivalent permeability. This discrepancy between PAMPA and Caco-2 results provides the first evidence that carrier-mediated transporters contribute to intestinal peptide absorption, particularly for polar peptides.
Why it matters
The inability to deliver peptide drugs orally is one of the biggest barriers in peptide therapeutics — most must be injected, limiting patient convenience and compliance. This study's demonstration that the intestine has active transport mechanisms for cyclic peptides opens a new strategy: instead of solely engineering peptides for passive membrane permeation (making them more fat-soluble), researchers could design peptides that harness the gut's own transport proteins to cross the intestinal wall. This could fundamentally change how oral peptide drugs are designed.
How the study worked
The study synthesized enantiomeric pairs of five N-methylated cyclic hexapeptides — three with polar character and two lipophilic. Lipophilicity was measured as logD at pH 7.4. Passive permeability was assessed using the parallel artificial membrane permeability assay (PAMPA), which uses a synthetic lipid membrane without biological components. Cellular permeability was measured using Caco-2 cell monolayers (a standard model of intestinal epithelium containing active transporters) in both directions across the cell layer.
What this study cannot tell us
The study used in vitro models (Caco-2 cells) that, while standard, may not fully recapitulate in vivo intestinal complexity including mucus layers, gut microbiome, and regional variations in transporter expression. The specific carrier proteins responsible for the differential transport were not identified. The number of peptide pairs tested was limited to five, so the generalizability of the finding to other peptide structures is uncertain. No in vivo absorption data was presented.
How to read the evidence
This is an in vitro mechanistic study using well-established permeability assays. The experimental design (comparing enantiomers to isolate transporter effects) is elegant and well-controlled, but the conclusions are limited to cell-based models and have not been validated in vivo.
When this study was published
Published in 2015, this study is about 11 years old. The finding about carrier-mediated peptide transport has influenced subsequent research on oral peptide design, and transporter-mediated strategies continue to be an active area of investigation.
The bigger picture
Oral delivery remains the holy grail of peptide drug development. The field has focused heavily on strategies to increase passive permeability — N-methylation, cyclization, and lipophilicity optimization — inspired by the natural product cyclosporine A. This study challenges that paradigm by showing that biological transporters, not just passive diffusion, play a role. If the specific transporters can be identified and exploited, it could enable a new generation of orally bioavailable peptide drugs that don't need to sacrifice polarity for absorption.
Questions still open
- Which specific intestinal transporter proteins are responsible for the carrier-mediated transport of these cyclic peptides?
- Can peptide drugs be rationally designed to exploit these transporters for improved oral bioavailability?
- Do these in vitro carrier-mediated transport differences translate to meaningful differences in oral absorption in animal models or humans?
Common questions
Why can't most peptide drugs be taken as pills?
What are enantiomers and why are they useful in this experiment?
Read the original research
Enantiomeric cyclic peptides with different Caco-2 permeability suggest carrier-mediated transport.
Chemistry (Weinheim an der Bergstrasse, Germany), 21(22), 8023-7
Citation
Marelli, Udaya Kiran; Bezençon, Jacqueline; Puig, Eduard; Ernst, Beat; Kessler, Horst. (2015). Enantiomeric cyclic peptides with different Caco-2 permeability suggest carrier-mediated transport.. Chemistry (Weinheim an der Bergstrasse, Germany), 21(22), 8023-7. https://doi.org/10.1002/chem.201501270